Patents/Assignees

Eli Lilly And Company

215 patents in portfolio

US11746115utility2023
Solid Forms of 7-[[(1s)-1-[4-[(1s)-2-cyclopropyl-1-(4-prop-2-enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4h-pyrimido[4,5-d][1,3]oxazin-2-one
0 cites
USD0997341design2023
Secured Medication Transfer Set
0 cites
US11730678utility2023
Secured Medication Transfer System
0 cites
US11731984utility2023
Kras G12C Inhibitors
0 cites
US11697647utility2023
RET Kinase Inhibitors
0 cites
USD0991270design2023
Display Screen with Animated Graphical User Interface
0 cites
USD0991286design2023
Display Screen with Animated Graphical User Interface
0 cites
USD0990659design2023
Needle Hub
0 cites
USD0989777design2023
Display Screen with a Graphical User Interface
0 cites
US11660407utility2023
Nasal Delivery Device with Safety Rod
0 cites
US11655214utility2023
Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl Compounds for the Treatment of Pancreatic Cancer
0 cites
US11655242utility2023
Glucagon-like Peptide1 Receptor Agonists
0 cites
USD0986413design2023
Drug Delivery Device
0 cites
US11649247utility2023
7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one Compounds as Mutant IDH1 and IDH2 Inhibitors
0 cites
US11649280utility2023
Antibodies to IL-34
0 cites
US11642467utility2023
Drive Assembly for Moving Piston Within Container
0 cites
US11638785utility2023
Medication Delivery Device with Sensing System
0 cites
US11634423utility2023
Substituted Pyrazolo[1,5-a]pyrimidines as Inhibitors of Interferon Signaling
0 cites
US11634426utility2023
Selective Estrogen Receptor Degraders
0 cites
US11634485utility2023
Therapeutic Antibody Formulation
0 cites

← PreviousPage 10 of 11Next →